PharmAbs, KU Leuven, Leuven, Belgium; Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, Leuven, Belgium.
Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium.
J Immunol Methods. 2022 Apr;503:113245. doi: 10.1016/j.jim.2022.113245. Epub 2022 Mar 4.
A multiplex assay for the quantitation of immunoglobulin G (IgG) serum antibodies directed against Clostridium tetani toxin (TT), Corynebacterium diphtheriae toxoid (DTxd), and the Bordetella pertussis antigens pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (Prn) was developed on an Evalution® platform to enhance the evaluation of the specific antibody response towards protein antigens in suspected humoral immunodeficiencies. Evalution® is a microfluidic and microparticle-based platform with the possibility to analyse single samples and to perform real-time kinetic measurements of antibody binding. All individual antigens were covalently linked to the carboxylated microparticles after which samples and fluorescently labelled detection antibodies were flowed over the microparticles in the microfluidic channels of the assay cartridges of the system. The developed assay showed very good sensitivity, specificity, and intra- and inter-assay coefficients of variation (CVs for the different antigens between 1.72-3.53% and 3.54-5.79%, respectively). Furthermore, the correlation of the Evalution pentaplex with a Luminex pentaplex using a panel of 48 human serum samples was excellent, with Spearman correlation coefficients between 0.936 for PT and 0.982 for DTxd (p < 0.0001 for all). Finally, we showed in a proof-of-concept experiment the potential of the Evalution® platform to simultaneously measure concentrations and binding kinetics (as a surrogate for avidity) of the IgG antibodies to the selected protein antigens. Overall, these findings show that this new Evalution pentaplex can accurately measure the antibody response to TT, DTxd, PT, FHA and Prn. It also has the potential to measure antibody binding and dissociation kinetics.
一种用于定量检测针对破伤风梭菌毒素(TT)、白喉类毒素(DTxd)和百日咳鲍特菌抗原百日咳毒素(PT)、丝状血凝素(FHA)和 pertactin(Prn)的 IgG 血清抗体的多重分析已在 Evalution®平台上开发,以增强对疑似体液免疫缺陷患者中针对蛋白质抗原的特异性抗体反应的评估。Evalution®是一种基于微流控和微颗粒的平台,具有分析单个样本和实时测量抗体结合的能力。所有单个抗原在羧基化微颗粒上共价连接,然后将样品和荧光标记的检测抗体流过系统的试剂盒分析盒微通道中的微颗粒。所开发的分析方法显示出非常好的灵敏度、特异性和批内及批间变异系数(不同抗原的变异系数分别为 1.72-3.53%和 3.54-5.79%)。此外,Evalution 五重分析与使用 48 个人类血清样本的 Luminex 五重分析的相关性非常好,Spearman 相关系数在 0.936(PT)和 0.982(DTxd)之间(所有 p 值均<0.0001)。最后,我们在一项概念验证实验中证明了 Evalution®平台同时测量选定蛋白质抗原的 IgG 抗体浓度和结合动力学(作为亲和力的替代指标)的潜力。总的来说,这些发现表明,这种新的 Evalution 五重分析可以准确测量针对 TT、DTxd、PT、FHA 和 Prn 的抗体反应。它还有潜力测量抗体结合和解离动力学。